Powered to cure
diabetic foot disease
from within

TRV-01 is the first-and-only skin graft technology that cures diabetic foot disease from within by treating the root causes of disease including increased angiogenesis and decreased cellular glycation of growth factor receptors.

Backed by a leadership team with years of experience bringing innovative biotech products to market, along with the most renowned scientific advisory board, Triovance has the expertise to succeed.

Triovance is proud to announce its selection as one of the finalists in the highly competitive INCIDE Booster Program, which aims to accelerate the development of innovative companies and academic institutions in the life sciences sector.